Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 190.24M P/E - EPS this Y - Ern Qtrly Grth -
Income -42.72M Forward P/E -7.89 EPS next Y - 50D Avg Chg -
Sales 3.84M PEG - EPS past 5Y - 200D Avg Chg 10.00%
Dividend N/A Price/Book 2.45 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.50 Quick Ratio 18.07 Shares Outstanding 145.26M 52W Low Chg 45.00%
Insider Own 0.01% ROA -16.67% Shares Float 1.27B Beta 1.94
Inst Own 3.70% ROE -26.21% Shares Shorted/Prior 4.80M/4.94M Price 2.13
Gross Margin - Profit Margin - Avg. Volume 1,697,561 Target Price 8.21
Oper. Margin -1,353.42% Earnings Date Aug 29 Volume 103,658 Change -1.84%
About Immutep Limited

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Limited News
12/17/24 Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
12/16/24 Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
12/13/24 Immutep announces results from Cohort B of TACTI-003 trial
12/12/24 Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
12/10/24 Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
12/06/24 Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million
11/14/24 Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
11/14/24 Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
11/06/24 Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago
10/29/24 Immutep Quarterly Activities Report Q1 FY25
10/28/24 Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
10/17/24 Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
10/10/24 Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
10/04/24 Immutep concludes participant enrolment in Phase II breast cancer trial
10/03/24 Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
09/24/24 Immutep Receives A$3.6 million R&D Tax Incentive from French Government
09/18/24 New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
09/16/24 Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
08/20/24 Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
08/14/24 Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
IMMP Chatroom

User Image SeatownGreen Posted - 8 hours ago

$IMMP Never been in a better position to hang out at the Superbowl of business development. Eftilagimod alpha has progressed to PH3 in NSCLC and IMP761 has rolled out 1st safety data in PH1. 👊

User Image Bigjezproduction Posted - 1 day ago

$IMMP https://www.nature.com/articles/s41598-024-83061-8

User Image MBFG09 Posted - 12/31/24

$IMMP year of disappointment

User Image bylocehi Posted - 12/30/24

$IMMP up 5% expect huge increase next year

User Image MBFG09 Posted - 12/30/24

$IMMP -16% this year Are we happy?? I don’t think

User Image bylocehi Posted - 12/27/24

$IMMP short interest increasing

User Image Geauxtigers47 Posted - 12/26/24

$IMMP good move today - let’s keep it going into the new year

User Image bylocehi Posted - 12/26/24

$IMMP if you can loan out shares for 23.5 % I am changing brokers

User Image bylocehi Posted - 12/26/24

$IMMP wow if you can get 24

User Image MBFG09 Posted - 12/26/24

$RLMD $PYXS $IMMP $EVH $CPRI 😭… will it finish this year … soon??

User Image ToRni27 Posted - 12/24/24

$IMMP Marc please make all trials 90mg Efti…. Thanks your shareholder🤞

User Image MBFG09 Posted - 12/24/24

$IMMP happy Christmas to all board and fantastic shareholders (really) 2024 a great year -17%

User Image fabiodic89 Posted - 12/24/24

$IMMP

User Image TheIrishCzar Posted - 12/23/24

$IMMP the interest rate is now 23.5%

User Image MBFG09 Posted - 12/23/24

$IMMP finally under 2$ Great Christmas Marc and Co. 😭

User Image Geauxtigers47 Posted - 12/23/24

$IMMP added

User Image tokar Posted - 12/23/24

$IMMP Lol all the gains from the recent good news is all gone. Terrible.

User Image MBFG09 Posted - 12/23/24

$IMMR $IMMP $PGY Flat

User Image Geauxtigers47 Posted - 12/23/24

$IMMP looks like sub $2 for Xmas- thanks Santa

User Image bylocehi Posted - 12/23/24

$IMMP currently sub cutaneous treatments when available are preferred over IV infusions, no ports less cost for adminstration Sq keytruda with eftilagimod will be the leading combo over any equivalent infusion therapy

User Image TheIrishCzar Posted - 12/23/24

$IMMP All if my shares are back on loan, now at 16% interest (highest i have gotten), which indicates how many are on loan; making them harder to get. This is also true for colleagues of mine. one of them is getting over 18.5%. This is obviously extremely expensive for whoever is borrowing and is likely a deep pocket institution. i do not believe they can be making profit on this. Are they borrowing to keep share price down? To get the votes?

User Image MBFG09 Posted - 12/23/24

$PYXS Friday, the shares of Pyxis Oncology Inc. (NASDAQ:PYXS), a biotechnology company focused on developing new cancer therapies, have received a revised price target from RBC Capital. The company's analyst changed the company's share price target to $8.00 from the previous $10.00, maintaining an Outperform rating on the stock. $IMMP $RLMD $CRVO stay tuned

User Image Bruyne Posted - 12/23/24

$IMMP For those who don’t follow Hot Copper…. https://www.csrxp.org/big-pharma-watch-merck-takes-another-step-toward-further-extending-patent-exclusivity-on-blockbuster-cancer-drug-keytruda/#:~:text=According%20to%20reporting%20from%20Reuters,expected%20as%20soon%20as%202028.”

User Image ToRni27 Posted - 12/22/24

$IMMP Marc please make all trials 90mg Efti…. Thanks your shareholder🤞

User Image Shanon Posted - 12/21/24

$IMMP Merry Christmas everyone, and Mr Green is back how good is that. We must be in for a great year ahead, bring on 2025. Welcome home, and everyone have a great new year.

User Image SeatownGreen Posted - 12/21/24

$IMMP Immutep seriously pulled it off. PH3 in the largest cancer indication paired with the top selling cancer therapeutic in the world. Godspeed physicians, families, and the brave patients enrolling in these trials. 👊

User Image MBFG09 Posted - 12/20/24

$IMMP very angry shareholders are very angry Disappointed

User Image TRUMP312SweepLandslide Posted - 12/20/24

$IMMP I bet Marc and the Seatown dude that disappeared both drive Jaguar’s….just a guess 🤷🏽‍♂️

User Image TRUMP312SweepLandslide Posted - 12/20/24

$IMMP Awesome! Nice lil 5% drop in final 30 minutes! Great job Marc….keep up the great work. Hope you can buy your family fantastic Christmas presents. IMMP shareholder’s….not so much!!!

User Image MBFG09 Posted - 12/20/24

$IMMP nice. Great -8-% this week We need resigns. …stop other games

Analyst Ratings
Baird Outperform Jun 27, 24
Capital One Overweight May 17, 24
Baird Outperform Aug 28, 23
Baird Outperform Aug 3, 23
Baird Outperform Aug 2, 23
Maxim Group Buy May 18, 23
Ladenburg Thalmann Buy Aug 3, 21
Maxim Group Buy May 29, 18